Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

G Emerens Wensink; Sjoerd G Elias; Jasper Mullenders; Miriam Koopman; Sylvia F Boj; Onno W Kranenburg; Jeanine M L Roodhart

doi:10.1038/s41698-021-00168-1

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

G Emerens Wensink, Sjoerd G Elias, Jasper Mullenders, Miriam Koopman, Sylvia F Boj, Onno W Kranenburg, Jeanine M L Roodhart

Research output: Contribution to journal › Review article › peer-review

7 Downloads (Pure)

Abstract

Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.

Original language	English
Article number	30
Journal	NPJ precision oncology
Volume	5
Issue number	1
DOIs	https://doi.org/10.1038/s41698-021-00168-1
Publication status	Published - 12 Apr 2021

Access to Document

10.1038/s41698-021-00168-1

s41698-021-00168-1Final published version, 2.64 MB

Cite this

@article{6c27c6d1ab2d42f8874b2e544d7b48d7,

title = "Patient-derived organoids as a predictive biomarker for treatment response in cancer patients",

abstract = "Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.",

author = "Wensink, {G Emerens} and Elias, {Sjoerd G} and Jasper Mullenders and Miriam Koopman and Boj, {Sylvia F} and Kranenburg, {Onno W} and Roodhart, {Jeanine M L}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = apr,

day = "12",

doi = "10.1038/s41698-021-00168-1",

language = "English",

volume = "5",

number = "1",

}

TY - JOUR

T1 - Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

AU - Wensink, G Emerens

AU - Elias, Sjoerd G

AU - Mullenders, Jasper

AU - Koopman, Miriam

AU - Boj, Sylvia F

AU - Kranenburg, Onno W

AU - Roodhart, Jeanine M L

PY - 2021/4/12

Y1 - 2021/4/12

N2 - Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.

AB - Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85109051137&partnerID=8YFLogxK

U2 - 10.1038/s41698-021-00168-1

DO - 10.1038/s41698-021-00168-1

M3 - Review article

C2 - 33846504

SN - 2397-768X

VL - 5

JO - NPJ precision oncology

JF - NPJ precision oncology

IS - 1

M1 - 30

ER -

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this